A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
A phase 1/2 trial of Clifutinib in acute myeloid leukaemia, run by Sunshine Lake Pharma Co., Ltd., now recruiting.
Overview
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML is a phase 1/2 interventional study registered as NCT05133882 by Sunshine Lake Pharma Co., Ltd., with 133 participants planned, started 2022-10-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Clifutinib Besylate.
Similar pages
not linked directly; found by shared links- TrialHEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Shares Clifutinib, Sunshine Lake Pharma (HEC), Acute myeloid leukaemia.
- TrialHEC169096 in Participants With Advanced Solid Tumors
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
- TreatmentLerotinib
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
- TrialMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialPhase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialClinical Study of U32 in Patients With Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialAn Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Acute myeloid leukaemia and the tag pipeline.